Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above

NCT05404945 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Classical Hodgkin Lymphoma

Interventions

DRUG: Pembrolizumab
DRUG: Doxorubicin
DRUG: Vinblastine
DRUG: Dacarbazine
DRUG: Brentuximab vedotin

Sponsor

University of Virginia

Collaborators

[object Object]